Back to first-pass browser

First-pass extracted concept

FAP-targeted CAR construct with 4-1BB costimulatory domain

Candidate: toolkit itemType: construct pattern1 source documents4 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

FAP-CAR, FAP-targeted CAR construct

Extracted Explainers

What the tool is doing

This construct is a second-generation FAP-targeted CAR incorporating a 4-1BB costimulatory domain. In the reported in vitro system, it enabled engineered Jurkat cells to recognize and kill FAP-expressing cardiac myofibroblasts.

Source 1DOIPubMed

Resources required

The abstract states that the construct was delivered using lentiviral vectors and lipid nanoparticles and tested in engineered Jurkat cells. Evaluation included CAR expression, target recognition, cytotoxicity, apoptosis, and IL-6 readouts.

Source 1DOIPubMed

What problem it solves

It addresses the lack of effective targeted therapies for myocardial fibrosis by enabling fibrosis-selective targeting of FAP-expressing cardiac myofibroblasts.

Source 1DOIPubMed

What it does not solve

The abstract does not show efficacy in primary T cells or in vivo cardiac fibrosis models. It therefore does not yet establish therapeutic performance beyond preliminary in vitro proof of concept.

Source 1DOIPubMed

Alternatives

The source contrasts two delivery approaches for generating engineered cells: lentiviral vectors and lipid nanoparticles. No direct comparator CAR architecture is tested within the abstract.

Source 1DOIPubMed

Evidence Snippets

we engineered a second-generation FAP-targeted CAR construct incorporating the 4-1BB costimulatory domain to enhance therapeutic safety
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1delivery approachsupports2025Source 1DOIPubMed

The study used lentiviral vectors and lipid nanoparticles to generate FAP-CAR-engineered Jurkat cells as a preliminary screening model.

Quoted textsource-backed
Using two delivery approaches-lentiviral vectors and lipid nanoparticles (LNPs)-we generated FAP-CAR-engineered Jurkat cells as a preliminary screening model
Claim 2engineering resultsupports2025Source 1DOIPubMed

The study engineered a second-generation FAP-targeted CAR construct incorporating the 4-1BB costimulatory domain.

Quoted textsource-backed
we engineered a second-generation FAP-targeted CAR construct incorporating the 4-1BB costimulatory domain
Claim 3functional activitysupports2025Source 1DOIPubMed

FAP-CAR-engineered Jurkat cells selectively recognized and induced apoptosis in FAP-expressing cardiac myofibroblasts.

Quoted textsource-backed
These engineered cells selectively recognized and induced apoptosis in FAP-expressing cardiac myofibroblasts
Claim 4safety signalsupports2025Source 1DOIPubMed

FAP-CAR-engineered Jurkat cells did not trigger excessive IL-6 secretion in the reported in vitro setting.

Quoted textsource-backed
without triggering excessive IL-6 secretion